NGL FINECHEM
|
The Current P/E Ratio of NGL FINECHEM is 42.88.
| Share Price | ₹1,430.7 | Jan 09,2026 |
| Market Cap | ₹887.0 Cr | |
| Earnings-TTM | ₹20.7 Cr | TTM-Consolidated Results |
| Price/Earnings | 42.88x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NGL FINECHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹887.0 Cr] as on Jan 09,2026
(/) Earnings [ ₹20.7 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 42.88x ]
Thus, for NGL FINECHEM , the investors are currently willing to pay 42.88 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NGL FINECHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NGL FINECHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of NGL FINECHEM
PE Ratio Performance Analysis for NGL FINECHEM
- NGL FINECHEM 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 28.31x.
- NGL FINECHEM 's operated at median p/e ratio of 31.37x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NGL FINECHEM 's p/e ratio peaked in Mar2023 at 36.22x.
- NGL FINECHEM 's p/e ratio hit its five-year low in Mar2021 of 16.74x.
How does NGL FINECHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NGL FINECHEM | 20.69 | 42.88 | 887.0 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 39.46 | 415,073.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 70.69 | 175,657.0 |
| CIPLA LTD | 5,453.86 | 21.72 | 118,431.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 62.67 | 134,121.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 17.64 | 100,944.0 |
| MANKIND PHARMA LTD | 1,767.06 | 51.39 | 90,806.8 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.11 | 90,052.9 |
| LUPIN LTD | 4,347.53 | 22.92 | 99,648.4 |
| AUROBINDO PHARMA LTD | 3,447.75 | 20.19 | 69,609.1 |
| ABBOTT INDIA LTD | 1,508.95 | 39.49 | 59,589.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NGL FINECHEM 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.64x |
| Max industry PE | 70.69x |
| Median industry PE | 39.46x |
| Average industry PE | 37.01x |
You may also like the below Video Courses